BloomZ Inc (BLMZ): Bloomz will leverage partnerships with C...

Bloomz will leverage partnerships with CrossVision Inc. and

Hafiq · 2024-10-14T16:10:29.7070000Z

Bloomz will leverage partnerships with CrossVision Inc. and sonilude Inc. to expand its animation production capabilities and further diversify its revenue streams. The related contracts could provide a much-needed boost to its growth strategy. Hidden gem.

Play Episode

7min

Proactive - Interviews for investors

European defense spending boom: Key investment opportunities amid global shifts

Jane Edmondson, Head of Index Product Strategy at TMXVettaFi, joined Steve Darling from Proactive to discuss the rapidly evolving global defense landscape and its investment implications. With geopolitical tensions on the rise and shifting defense priorities, investors must navigate new opportunities and risks in the sector. Edmondson highlighted Europe's unprecedented surge in defense spending, a direct response to the U.S. decision to scale back military aid to Ukraine. Central to this shift is the European Union’s €800 billion "Rearm Europe Readiness 2030" initiative, aimed at bolstering military preparedness. This includes substantial investments across key defense technologies and a dedicated €150 billion credit facility to enhance military capabilities. “There’s going to be a lot of spending to come,” Edmondson noted, emphasizing major growth areas such as artificial intelligence, cyber defense, drone technology, and advanced artillery systems. She pointed out that leading European defense firms—including Rheinmetall, BAE Systems, Thales, Dassault, and Leonardo SPA—stand to benefit significantly from this expansion. Additionally, South Korea’s Hanwha Aerospace is emerging as a key player in global defense contracts. In contrast, U.S. defense companies are experiencing headwinds due to budget cuts and canceled procurement deals, leading to a relative downturn in the sector. Another critical shift in global defense procurement is unfolding as traditional U.S. allies reconsider their defense purchases. Canada and Portugal, for instance, are re-evaluating orders for U.S.-made F-35 fighter jets in favor of alternative options, such as aircraft from Dassault Aviation. Edmondson stressed that these geopolitical realignments are creating strong economic tailwinds, particularly for Germany, which is set to invest an estimated €500 billion in defense over the next several years. She cited a recent Goldman Sachs report, which projects that half of this spending will

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

2D Photonics CEO discusses plans to scale up advanced graphene-based photonics technology

Frontier IP Group portfolio company 2D Photonics CEO Ben Jensen talked with Proactive's Stephen Gunnion about the company’s recent €25 million funding round and its plans to scale up its advanced graphene-based photonics technology. Jensen explained the growing demand for faster, more cost-effective data transmission solutions, driven by sectors such as AI and 5G. “What’s required today is ever faster data transmission at lower costs,” he said. According to Jensen, the new device architecture 2D Photonics has developed simplifies photonics design while significantly improving performance. This innovation is crucial for enabling higher bandwidth and lower power consumption across data networks. The funding will support the expansion of the leadership team and the development of pilot production capabilities. Jensen emphasized the importance of execution at this early stage, noting that the goal is to demonstrate the scalability of the technology for semiconductor foundries and ultimately reach high-volume manufacturing. He also discussed future applications, pointing to sectors such as space and defence, where rugged environments make traditional photonics challenging. In addition, the technology has relevance for Advanced Driver-Assistance Systems (ADAS), where rapid data transmission between sensors is critical for vehicle safety. Visit Proactive’s YouTube channel for more insightful interviews like this. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #GraphenePhotonics #2DPhotonics #FrontierIPGroup #DataTransmission #SemiconductorTech #ADAS #SpaceTech #PhotonicsInnovation #GrapheneTech #DeepTechStartups #HighSpeedData #BenJensen #ProactiveInvestors

Proactive - Interviews for investors

St George Mining unveils major JORC resource

St George Mining Ltd executive chairman John Prineas talked with Proactive about the company's newly announced maiden JORC resource, which he says could be among the world’s most significant niobium and rare earth deposits. Prineas said the deposit features over 500 intercepts of high-grade mineralisation and boasts a rare combination of high grades and shallow mineralisation starting at surface, supporting an open pit development. “We think, possibly the second highest niobium deposit in terms of grade and, probably one of the highest rare earth deposits,” he told Proactive. He confirmed the company has already seen interest from industry players, with some expressing interest in potential partnerships and even mergers. The resource was released following St George’s acquisition of the project in late February, and the company has committed to a drill program starting in the coming weeks. According to Prineas, this program could potentially double the existing resource. In Brazil, St George has assembled an experienced in-country team and engaged a global EPC contractor to progress mine development. The company has also begun metallurgical and downstream processing studies and believes the project will deliver a commercial-grade product, supported by decades of similar production by neighbours CBMM. 👉 For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and enable notifications so you never miss an update. #StGeorgeMining #Niobium #RareEarths #JORCResource #MiningExploration #ASX #CriticalMinerals #BrazilMining #ResourceUpdate #MineralDiscovery #JohnPrineas #ProactiveInvestors

Followers	0
Posts	1
Boards Moderated	0
Alias Born	10/14/2024

Volume:	1,445,004
Day Range:	0.146 - 0.202
Bid:	0.155
Ask:	0.1649
Last Trade Time:	7:48:02 PM EDT
Total Trades:	4,073

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BLMZ Detailed Quote

Recent BLMZ News

More BLMZ News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BLMZ News

Go Ad-Free